<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JDM</journal-id><journal-title-group><journal-title>Journal of Diabetes Mellitus</journal-title></journal-title-group><issn pub-type="epub">2160-5831</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jdm.2017.71003</article-id><article-id pub-id-type="publisher-id">JDM-74242</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Clinical Parameters of Metabolic Control (HbA&lt;sub&gt;1c&lt;/sub&gt;) and Deterioration of Peripheral Arterial Perfusion in Type 2 Diabetes
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ma.</surname><given-names>de Lourdes Zúñiga-Martínez</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yolanda</surname><given-names>Terán-Figueroa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Laura</surname><given-names>Escarlet Guerrero-Cruz</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ángel</surname><given-names>Antonio Vértiz-Hernández</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Academic Coordination Altiplano Region, Autonomous University of San Luis Potosi, San Luis Potosi, Mexico</addr-line></aff><aff id="aff2"><addr-line>Faculty of Nursing and Nutrition, Autonomous University of San Luis Potosi, San Luis Potosi, Mexico</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>yolandat@uaslp.mx(YT)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>01</month><year>2017</year></pub-date><volume>07</volume><issue>01</issue><fpage>31</fpage><lpage>39</lpage><history><date date-type="received"><day>December</day>	<month>7,</month>	<year>2016</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>February</month>	<year>18,</year>	</date><date date-type="accepted"><day>February</day>	<month>21,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective: To determine the relationship between clinical parameters (HbA
  <sub>1c</sub>) whit metabolic control and deterioration of peripheral arterial perfusion in diabetic patients. 
  Methodology: 108 medical records of patients with type 2 diabetes mellitus were evaluated. We obtained averages of: blood glucose (162.3 &#177; 73.10 mg/dl), glycated hemoglobin (HbA
  <sub>1c</sub> = 7.64% &#177; 1.77%), cholesterol (189.28 &#177; 35.25 mg/dl), triglycerides (189.11 &#177; 87.76 mg/dl), Systolic Blood Pressure (SBP = 119.69 &#177; 14.95 mmHg), Diastolic Blood Pressure (DBP = 77.15 &#177; 9.55 mmHg) and Media Blood Pressure (MBP = 91.36 &#177; 9.89 mmHg). We correlated variable HbA
  <sub>1c</sub> with vascular injury symptomatology. 
  Results: Correlation was found between sensitivity dysfunction and HbA
  <sub>1c</sub> with a statistical significance of p = 0.01, and a correlation Kendal coefficient w = 0.01, any other parameter of metabolic control was not correlated with symptoms of vascular injury. 
  Conclusion: It is remarkable that the sensitivity dysfunction is a symptom of poorly vascularized lower extremities caused for both functional impairment and structural changes in diabetic patients’ peripheral nerves, even in the preclinical stage of vascular disease. The HbA
  <sub>1c</sub> could also be investigated as a likely sensitivity dysfunction biomarker in DM due to the correlation presented in this study but more studies must be realized.
 
</p></abstract><kwd-group><kwd>Protein Glycation</kwd><kwd> Vascular Disease</kwd><kwd> HbA&lt;sub&gt;1c&lt;/sub&gt;</kwd><kwd> Type 2 Diabetes Mellitus</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Diabetes mellitus (DM) remains a major health care problem worldwide due to associated complications and prevalence both in developing and developed countries [<xref ref-type="bibr" rid="scirp.74242-ref1">1</xref>] . The people with it face an array of health issues such as: 1) It is the leading cause of lower-limb amputation non-traumatic, new cases of blindness, and kidney failure complications that affect the daily activity; 2) It is also a major contributor to cardiovascular disease, the number one cause of death in world. It is predicted that within 15 years (2030), there will be 500 million people worldwide with diabetes if we do not take the necessary measures to prevent the spread of this serious and costly disease.</p><p>The medical costs for treating patients with DM represent an important spending, the projections for 2020 close to 200 billion USD, or even higher. It also causes loss of productivity resulting in spend for the patient and his family [<xref ref-type="bibr" rid="scirp.74242-ref2">2</xref>] . In Mexico, the National Institute of Public Health (2010), ranked the DM as third cause of disability in men and the fifth in the women [<xref ref-type="bibr" rid="scirp.74242-ref3">3</xref>] , 80% of the disabilities in diabetics are caused for vascular complications could be averted through adequate prevention and early intervention. The strategies are focused on prevention and intensive treatment and are cost-effective when the first focus on people at high risk of developing the disease and second in hypertension control, cholesterol and glucose levels among diagnosed people [<xref ref-type="bibr" rid="scirp.74242-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref5">5</xref>] .</p><p>In the past two decades, they have accumulated considerable evidence that supporting the potentially pathogenic role of some number of mechanisms that lead to the development of vascular complications mainly the diabetic foot among which are: nerve ischemia, oxidative stress, glycosylation and products and other molecular disorders. These changes cause damage to nerve fibers and lead to the development of peripheral vascular disease where endothelial dysfunction is the most serious result as it affects limb microcirculation [<xref ref-type="bibr" rid="scirp.74242-ref6">6</xref>] .</p><p>The chronic hyperglycemia in diabetic patients leads to changes at biomolecular, anatomical and physiologic level. These changes induce the development of vascular complications such as the peripheral arterial disease (PAD) and thus to poorly vascularized extremities whit considerable risk for amputation contribute to diminished quality of life and even death of diabetics [<xref ref-type="bibr" rid="scirp.74242-ref7">7</xref>] .</p><p>Advanced glycation end products (AGEs) contribute to a variety of microvascular and macrovascular injuries mostly leads to Peripheral Vascular Disease (PVD) cause of blindness, chronic renal failure and nontraumatic lower-limb amputation in diabetic patient in Mexico [<xref ref-type="bibr" rid="scirp.74242-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref9">9</xref>] . The National Nutrition Health Survey in 2012 [<xref ref-type="bibr" rid="scirp.74242-ref5">5</xref>] founded 38% (2.4 millions) of patients with a previous DM diagnosis reported the presence of burning, pain or loss of sensation in the feet. Besides, also reported a prevalence of amputations or 2% (182 thousand people) and the latter were associated with an evolution of the disease of approximately 12 years [<xref ref-type="bibr" rid="scirp.74242-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref10">10</xref>] . Nontraumatic lower-limb amputation is usually preceded by a foot ulcer in 85% of patients, and cases so that the association between ulcers and lower limb amputations is obvious, it is also known that patients require subsequent amputation and that the greater part of the amputated, there are higher risk of death within 5 years [<xref ref-type="bibr" rid="scirp.74242-ref11">11</xref>] .</p><p>In general terms, Treatment of Peripheral Vascular Disease (PVD), like other complications of DM, should focus first on metabolic control and then the specific actions, that is, emphasize early detection risk factors such as: hyperglycemia, dyslipidemia, hypertension, etc. [<xref ref-type="bibr" rid="scirp.74242-ref8">8</xref>] . In some contexts of health, as in some Mexican provinces, is difficult to carry out good metabolic control in patients with DM as it has not reactive required for this, it is why it is necessary to have risk markers with high specificity and sensitivity in identifying PVD.</p><p>This study addresses the issue on the identification of risk markers to determine the peripheral vascular damage in patients with Type 2 DM, specifically HbA<sub>1c</sub>, so as to enable health personnel identify potential damage service users and intervene in an effective and timely manner. 97% of hemoglobin corresponding to a molecular form represented as HbA1, 2.5% or less to HbA2 form and less than 1% to the HbF form the union of different sugars favors the formation of HbA<sub>1a</sub>, HbA<sub>1b</sub> y HbA<sub>1c</sub>; the latter is the most abundant (approximately 80%) in the bloodstream. HbA<sub>1c</sub> it has been used for over 10 years, to establish the diagnosis of DM in different populations, to determine the degree of metabolic control that the patient has had in the last three months and as a marker of coronary risk tissue [<xref ref-type="bibr" rid="scirp.74242-ref12">12</xref>] . The purpose of this study was to establish whether there a relationship between clinical parameters of metabolic control (blood pressure, plasma glucose, triglycerides and HbA<sub>1c</sub>) with the deterioration of peripheral arterial perfusion in patients with a clinical diagnosis of type 2 DM current or later production of electronic products.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Design and Sample Size</title><p>This study was documentary quantitative and the study subjects were clinical records of patients with type 2 Dibetes Mellitus and deterioration of peripheral arterial perfusion symptoms (n = 108 records). The inclusion criteria were patients with type 2 DM records with follow-up consultation record (of one year); patients who have test HbA<sub>1c</sub> results, blood glucose, cholesterol, triglycerides and that the clinical records mentions the presence of symptomatology of vascular dysfunction. The exclusion criteria were records of diabetic patients with any type of anemia, with renal failure and iron pharmacological therapy. These three conditions alter the results of glycosylated hemoglobin.</p></sec><sec id="s2_2"><title>2.2. Data Collection</title><p>The parameters obtained were: HbA<sub>1c</sub>, blood glucose, blood pressure (BP), Mean Arterial Pressure (MAP), cholesterol and triglycerides these values were related with skin disorders or signs and symptoms to deterioration of peripheral arterial perfusion.</p></sec><sec id="s2_3"><title>2.3. Data Assessment</title><p>The clinical parameters were related with the percentages of symptoms related to vascular damage and overall error and standard deviation of each variable was calculated. The Pearson correlation coefficient (r=) Kendall coefficient, (w=) between HbA<sub>1c</sub> and decreased peripheral pulses, paleness in lower limbs, delayed capillary refill, changes in temperature, sensitivity dysfunction, alteration nailbeds, onychomycosis, venous insufficiency ulcers, hyperkeratosis were obtained.</p></sec><sec id="s2_4"><title>2.4. Ethical Concerns of the Study</title><p>The development of this research was based on Article 17 of the General Health Law in research without risk [<xref ref-type="bibr" rid="scirp.74242-ref13">13</xref>] . The protocol included the authorization of general manager of Mexican Social Security Institute (Clinic 14, in March 7, 2016; number of trade Of. Dir. 084/16).</p></sec></sec><sec id="s3"><title>3. Results</title><p>The records were constituted for 82 women files and 26 men files (n = 108) in this study. In the clinical records the patients were 59.19 &#177; 13.86 years old and the predominant marital status was married with 76.9%, the single status was 0.9%. The year’s evolution for the disease had an average of 9.12 &#177; 6.42 years (see <xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The average of clinical disease evolution was 9.12 &#177; 6.42 years and the metabolic control parameters with 12 months of follow-up are on the <xref ref-type="table" rid="table1">Table 1</xref>, nevertheless, the greater data deviation was plasma glucose (&gt;140 mg/dL), followed cholesterol (&lt;160 mg/dl), see <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>No results found of decreased peripheral pulses, delay in capillary refill, and changes in temperature or pain nevertheless, our results showed that paleness of the limbs had an average of 4.26% &#177; 0.79%, sensitivity dysfunction was 2.93% &#177;</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic data of patients with type 2 diabetes mellitus (n = 108)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Sex</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >Distribution of patients by sex</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Frequency</td><td align="center" valign="middle"  colspan="2"  >Percentage</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle"  colspan="2"  >82</td><td align="center" valign="middle"  colspan="2"  >76%</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle"  colspan="2"  >26</td><td align="center" valign="middle"  colspan="2"  >24%</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle"  colspan="2"  >810</td><td align="center" valign="middle"  colspan="2"  >100%</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="4"  >Age of patients</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Minimum</td><td align="center" valign="middle" >Maximum</td><td align="center" valign="middle" >Average</td><td align="center" valign="middle" >Standard deviation</td></tr><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >59.19</td><td align="center" valign="middle" >13.86</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Distribution of patients by marital status</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >Frequency</td><td align="center" valign="middle"  colspan="2"  >Percentage</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Married</td><td align="center" valign="middle" >83</td><td align="center" valign="middle"  colspan="2"  >76.9%</td></tr><tr><td align="center" valign="middle" >Single</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle"  colspan="2"  >0.9%</td></tr><tr><td align="center" valign="middle" >Widower</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20</td><td align="center" valign="middle"  colspan="2"  >18.5%</td></tr><tr><td align="center" valign="middle" >Free Union</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4</td><td align="center" valign="middle"  colspan="2"  >3.7%</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >108</td><td align="center" valign="middle"  colspan="2"  >100%</td></tr><tr><td align="center" valign="middle"  colspan="5"  >Years of evolution of Diabetes Mellitus in study subjects</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Minimum</td><td align="center" valign="middle" >Maximum</td><td align="center" valign="middle" >Average</td><td align="center" valign="middle" >Standard deviation</td></tr><tr><td align="center" valign="middle" >Years of progression disease</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >9.12</td><td align="center" valign="middle" >6.462</td></tr></tbody></table></table-wrap><p>1.67%, presence of recorded edema was 4.5% &#177; 2.01%, alteration in nail beds found an average of 2.70% &#177; 1.25% among others parameters (see <xref ref-type="table" rid="table3">Table 3</xref>).</p><p>In relation with the correlation of variables, we found no statistical significance between most of them except as regards HbA<sub>1c</sub> and the presence of altered sensitivity. Pearson correlation coefficient was r = −0.20, with a value p &lt; 0.50. Regarding the correlation coefficient Kendall, it was w = 0.01, with a value p &lt; 0.01, which is statistically significant (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Average clinical parameters of metabolic control in patients with type 2 diabetes mellitus (n = 108)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Glucose</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/3-4300404x2.png" xlink:type="simple"/></inline-formula></th><th align="center" valign="middle" >Cholesterol</th><th align="center" valign="middle" >Triglycerides</th><th align="center" valign="middle" >SBP<sup>2</sup></th><th align="center" valign="middle" >DBP<sup>3</sup></th><th align="center" valign="middle" >MBP<sup>4</sup></th></tr></thead><tr><td align="center" valign="middle" >Average</td><td align="center" valign="middle" >162.36 md/dL</td><td align="center" valign="middle" >7.64%</td><td align="center" valign="middle" >189.11 md/mL</td><td align="center" valign="middle" >189.11 md/mL</td><td align="center" valign="middle" >119.69 mmHg</td><td align="center" valign="middle" >77.15 mmHg</td><td align="center" valign="middle" >91.36 mmHg</td></tr><tr><td align="center" valign="middle" >Standard deviation</td><td align="center" valign="middle" >73.10</td><td align="center" valign="middle" >1.17</td><td align="center" valign="middle" >35.25</td><td align="center" valign="middle" >87.76</td><td align="center" valign="middle" >14.95</td><td align="center" valign="middle" >1.43</td><td align="center" valign="middle" >9838</td></tr><tr><td align="center" valign="middle" >Standard error</td><td align="center" valign="middle" >7.03</td><td align="center" valign="middle" >0.17</td><td align="center" valign="middle" >3.39</td><td align="center" valign="middle" >8.44</td><td align="center" valign="middle" >9.55</td><td align="center" valign="middle" >0.91</td><td align="center" valign="middle" >0.95</td></tr></tbody></table></table-wrap><p>Data represent <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/3-4300404x3.png" xlink:type="simple"/></inline-formula> &#177; DE a monthly readings of a study records corresponding to patients with Type 2 DM. <sup>1</sup>Glycated hemoglobin fraction 1c, <sup>2</sup>Systolic Blood Pressure, <sup>3</sup>Diastolic Blood Pressure, <sup>4</sup>Media Blood Pressure.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Average values of the different symptoms of vascular damage (n = 108)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Symptoms of vascular damage</th><th align="center" valign="middle" >Average (%)</th><th align="center" valign="middle" >Standard deviation (%)</th><th align="center" valign="middle" >Standard error (%)</th></tr></thead><tr><td align="center" valign="middle" >Paleness of the lower extremity</td><td align="center" valign="middle" >4.26</td><td align="center" valign="middle" >0.79</td><td align="center" valign="middle" >0.07</td></tr><tr><td align="center" valign="middle" >Sensitivity dysfunction</td><td align="center" valign="middle" >2.93</td><td align="center" valign="middle" >1.67</td><td align="center" valign="middle" >0.16</td></tr><tr><td align="center" valign="middle" >Edema</td><td align="center" valign="middle" >4.5</td><td align="center" valign="middle" >2.01</td><td align="center" valign="middle" >0.19</td></tr><tr><td align="center" valign="middle" >Alteration nailbeds</td><td align="center" valign="middle" >2.70</td><td align="center" valign="middle" >1.25</td><td align="center" valign="middle" >0.11</td></tr><tr><td align="center" valign="middle" >Onychomycosis</td><td align="center" valign="middle" >39.59</td><td align="center" valign="middle" >8.57</td><td align="center" valign="middle" >0.82</td></tr><tr><td align="center" valign="middle" >Venous insufficiency</td><td align="center" valign="middle" >38.24</td><td align="center" valign="middle" >9.78</td><td align="center" valign="middle" >0.94</td></tr><tr><td align="center" valign="middle" >Ulcers</td><td align="center" valign="middle" >0.63</td><td align="center" valign="middle" >0.70</td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >Hyperkeratosis</td><td align="center" valign="middle" >8.57</td><td align="center" valign="middle" >1.58</td><td align="center" valign="middle" >0.15</td></tr></tbody></table></table-wrap><p>Data represent <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/3-4300404x4.png" xlink:type="simple"/></inline-formula> &#177; DE a monthly readings of a study records corresponding to patients with Type 2 DM.</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Correlation between HbA1c variable with the sensitivity dysfunction. (Data represent % of HbA<sub>1c</sub> and % of sensitivity dysfunction an average of 12 months; n = 108; p &lt; 0.01)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/3-4300404x5.png"/></fig></sec><sec id="s4"><title>4. Discussion</title><p>Diabetes and its complications put a great economic burden on patients, their families, healthcare systems and countries [<xref ref-type="bibr" rid="scirp.74242-ref1">1</xref>] . A correlation was found between the awareness about the disease complications and mean self-care agency scores of the diabetic subjects. Those who were aware of disease complications had higher self-care agency scores than those who were unaware of them [<xref ref-type="bibr" rid="scirp.74242-ref14">14</xref>] . However, a study showed that there was no significant correlation between the presence of complications and self-care [<xref ref-type="bibr" rid="scirp.74242-ref15">15</xref>] .</p><p>Our results show a clear metabolic breakdown in all patients throughout the study period since each parameter was found to be well above normal values [<xref ref-type="bibr" rid="scirp.74242-ref16">16</xref>] . In spite of the above, we did not find statistical relation of the registered parameters and symptomatology of vascular damage except between HbA<sub>1c</sub> and sensitivity dysfunction, which is consistent with studies that have associated HbA<sub>1c</sub> as a marker of risk with cardiovascular disease [<xref ref-type="bibr" rid="scirp.74242-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref21">21</xref>] , mainly in coronary arteries, not in damage to other organs such as the kidney [<xref ref-type="bibr" rid="scirp.74242-ref22">22</xref>] or liver [<xref ref-type="bibr" rid="scirp.74242-ref23">23</xref>] . Ramesh and col (2015), evaluated the role of hepato-biliary function as a marker of predictor Coronary Artery Disease (CAD) in patient with Type 2 DM. 100 subjects included 50 T2DM patients with CAD and 50 T2DM without CAD were evaluated and their finding implies that decreased serum bilirubin increases the risk of CAD in patients with Type 2 DM and it shows inverse correlation between HbA<sub>1c</sub> and bilirubin [<xref ref-type="bibr" rid="scirp.74242-ref24">24</xref>] .</p><p>On the other hand, results found in our study regarding the symptomatology of sensitivity dysfunction differ from those reported by different authors [<xref ref-type="bibr" rid="scirp.74242-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref27">27</xref>] , studies in which, claudication and pain are the most prevalent symptoms in the PVD during stadiums I and II. In the present study, the most prevalent symptom was the presence of onychomycosis followed by hyperkeratosis, probably due to changes in endothelial cell proliferation which compromise the activity of the immune system-inhibition of fibroblasts and damage to the basement membrane of keratinocytes [<xref ref-type="bibr" rid="scirp.74242-ref27">27</xref>] . Hyperkeratosis has been associated with collagen glycosylation in keratinocytes which results in thick skin, dry and rough in the lower limbs and its presence has been associated with ulcerations in the diabetic foot [<xref ref-type="bibr" rid="scirp.74242-ref28">28</xref>] .</p><p>Presence of sensitivity dysfunction is the main symptom of diabetic polyneuropathy―loss of peripheral nerve fiber function―considered the most common predictor of diabetic foot ulceration and symptom associated with a lack of metabolic control of the patient [<xref ref-type="bibr" rid="scirp.74242-ref29">29</xref>] . This result indicates that HbA<sub>1c</sub> could also be investigated as a likely marker of risk of diabetic neuropathy―Necessary condition for the appearance of ulcers in Type 2 DM patients. In other studies [<xref ref-type="bibr" rid="scirp.74242-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.74242-ref31">31</xref>] HbA<sub>1c</sub> has shown its effectiveness both in the diagnosis of Type 2 DM, as well as cardiovascular risk, damage to the retina and diagnosis of DM. There are no other studies related to HbA<sub>1c</sub> and sensitivity dysfunction in lower limbs.</p></sec><sec id="s5"><title>5. Conclusions and Suggestions</title><p>- In this study, a correlation was established between HbA1c and sensitivity dysfunction in lower limbs.</p><p>- The correlation found in this study is an important finding of clinical impact which would allow emphasizing the importance of metabolic control through the measurement of HbA1c in patients with Type 2 DM.</p><p>- The authors suggest that this positive correlation can be used as a likely marker of loss of sensitivity.</p></sec><sec id="s6"><title>Conflict of Interests</title><p>The authors declare that they have no conflict of interests.</p></sec><sec id="s7"><title>Authors’ Contribution</title><p>This study was designed by Ma. de Lourdes Z&#250;&#241;iga-Mart&#237;nez and &#193;ngel Antonio V&#233;rtiz-Hern&#225;ndez. Patient selection and data collecting were organized and made by Yolanda Ter&#225;n-Figueroa and Laura Escarlet Guerrero-Cruz Statistical analyses were done by &#193;ngel Antonio V&#233;rtiz-Hern&#225;ndez, statistical expert. The paper was written by Ma. de Lourdes Z&#250;&#241;iga-Mart&#237;nez, Yolanda Ter&#225;n-Figueroa and &#193;ngel Antonio V&#233;rtiz-Hern&#225;ndez.</p></sec><sec id="s8"><title>Cite this paper</title><p>de Lourdes Z&#250;&#241;i- ga-Mart&#237;nez, Ma., Ter&#225;n-Figueroa, Y., Gu- errero-Cruz, L.E. and V&#233;rtiz-Hern&#225;ndez, &#193;.A. (2017) Clinical Parameters of Metabolic Con- trol (HbA<sub>1c</sub>) and Deterioration of Periphe- ral Arterial Perfusion in Type 2 Diabetes. Journal of Diabetes Mellitus, 7, 31-39. https://doi.org/10.4236/jdm.2017.71003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.74242-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">T. R. Ministry of Health Public Health Agency of Turkey (2014) Turkey Diabetes Program 2015-2020. The Kuban Printing Publishing, Ankara.</mixed-citation></ref><ref id="scirp.74242-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">International Diabetes Federation (2008) International Curriculum for Diabetes Health Professional Education. B-1000 Brussels, 30-45.</mixed-citation></ref><ref id="scirp.74242-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lozano, R., Gómez-Dantés, H., Garrido-Latorre, F., Jiménez-Corona, A., Campuzano-Rincón, J., Franco-marina, F., Medina-Mora, M., et al. (2013) Burden of Disease, Injuries, Risk Factors and Challenges for the Health System in Mexico. Salud Pública de México, 55, 580-594. https://doi.org/10.21149/spm.v55i6.7304</mixed-citation></ref><ref id="scirp.74242-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Escobar, C., Blanes, I., Ruíz, A., Vinuesa, D., Montero, M., Rodríguez, M., Barbera, G. and Manzano, L. (2011) Prevalence and Clinical Profile and Management of Peripheral Arterial Disease in Elderly Patients with Diabetes. Europan Journal of Internal Medicine, 22, 275-281. https://doi.org/10.1016/j.ejim.2011.02.001</mixed-citation></ref><ref id="scirp.74242-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hernández-ávila, M., Gutiérrez, J. and Reynoso-Noverón, N. (2013) Diabetes Mellitus in Mexico. Status of the Epidemic. Salud Pública de México, 55, SI 29-SI 36.</mixed-citation></ref><ref id="scirp.74242-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Okosun, I., Seale, P., Lyn, R. and Davis-Smith, M. (2015) Improving Detection of Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests. Frontiers in Public Health, 3, 260. https://doi.org/10.3389/fpubh.2015.00260</mixed-citation></ref><ref id="scirp.74242-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Guzmán, J.R., Lyra, R., Aguilar-Salinas, C., Cavalcanti, S., Escano, F., Tambasia, M. and Duarte, E. (2010) Treatment of Type 2 Diabetes in Latin America: A Consensus Statement by the Medical as Associations of 17 Latin American Countries. Pan American Journal of Public Health, 28, 463-471.  
https://doi.org/10.1590/S1020-49892010001200008</mixed-citation></ref><ref id="scirp.74242-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Health Secretary (2013) Diagnosis, Outpatient Control Goals and Timely Reference to Pre-Diabetes and Diabetes Mellitus Type 2 in Adults at the First Level of Care. Health Secretary, Mexico.</mixed-citation></ref><ref id="scirp.74242-ref9"><label>9</label><mixed-citation publication-type="book" xlink:type="simple">Aguilar, F.R., Terán, J. and Escobedo, J.D. (2011) The Pathogenesis of the Diabetic Foot Ulcer: Prevention and Management. In: Dinh, T., Ed., Global Perspective on Diabetic Ulcerations, In Tech, 155-182. https://doi.org/10.5772/30325</mixed-citation></ref><ref id="scirp.74242-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Healh Secretary, National Commission for Social Protection in Health, Human Development Program Opportunities, Institute of Security and Social Services for State Workers, National Institute of Public Health. National Health and Nutrition Survey 2012 (ENSANUT). United States of Mexico, 2012.</mixed-citation></ref><ref id="scirp.74242-ref11"><label>11</label><mixed-citation publication-type="book" xlink:type="simple">Bowker, J. and Pfeifer, M. (2011) Major and Minor Amputations and Dislocations of the Lower Limb in Patients with Diabetes Mellitus. In: Levin and O’Neal, Eds., The Diabetic Foot, Elsevier Mosby, Espana, 409-412.</mixed-citation></ref><ref id="scirp.74242-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Hernández, G.A., Jiménez, A.A. and Bacardí, M.G. (2015) Effect of Carbohydrate Diets on Weight Loss and Glycosylated Hemoglobin in People with Type 2 Diabetes: Systematic Review. Hospital Nutrition, 32, 1960-1966.</mixed-citation></ref><ref id="scirp.74242-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">General Secretariat, Office of Parliamentary Services, Chamber of Deputies of the H. Congress of the Union (2016) General Law of Health. United Mexican States.</mixed-citation></ref><ref id="scirp.74242-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Istek, N. and Karakur, P. (2016) Effect of Activities of Daily Living on Self-Care Agency in Individuals with Type 2 Diabetes. Journal of Diabetes Mellitus, 6, 247-262. http://www.scirp.org/journal/jdm  
https://doi.org/10.4236/jdm.2016.64026</mixed-citation></ref><ref id="scirp.74242-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J., Wang, J., Zheng, P., Haardorfe, R., Kegler, M.C., Zhu, Y. and Fu, H. (2013) Effects of Self-Care, Self-Efficacy, Social Support on Glycemic Control in Adults with Type 2 Diabetes. BMC Family Practice, 14, 66.  
https://doi.org/10.1186/1471-2296-14-66</mixed-citation></ref><ref id="scirp.74242-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Health Secretary (2003) Official Mexican Standard NOM 037-SSA2-2002, for Prevention, Treatment and Control of Dyslipidemias.  
http://www.salud.gob.mx/unidades/cdi/nom/037ssa202.html</mixed-citation></ref><ref id="scirp.74242-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Arnold, L.W., Hoy, W.E., Sharma, S.K. and Wand, Z. (2016) The Association between HbA1c and Cardiovascular Disease Markers in a Remote Indigenous Australian Community with and without Diagnosed Diabetes. Journal of Diabetes Research, 2016, Article ID: 5342304. https://doi.org/10.1155/2016/5342304</mixed-citation></ref><ref id="scirp.74242-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lu, J., Bi, Y., Wang, T., Wang, W., Mu, Y., Zhao, J., Liu, Ch., Chen, L., Shig, L., Li, Q., Wan, Q., Wu, S., Qin, G., Yang, T., Yan, L., Liu, Y., Wang, G., Luo, Z., Tang, X., Chen, G., Huo, Y., Gao, Z., Su, Q., Ye, Z., Wang, Y., Deng, H., Yu, X., Shen, F., Chen, L., Zhao, L., Dai, M., Xu, M., Xu, Y., Chen, Y., Lai, S. and Ning, G. (2014) The Relationship between Insulin-Sensitive Obesity and Cardiovascular Diseases in a Chinese Population: Results of the REACTION Study. International Journal of Cardiology, 172, 388-394. https://doi.org/10.1016/j.ijcard.2014.01.073</mixed-citation></ref><ref id="scirp.74242-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sahu, A., Gupta, T., Kavishwar, A. and Singh, R.K. (2015) Cardiovascular Diseases Risk Prediction by Homocysteine in Comparison to Other Markers: A Study from Madhya Pradesh. Journal of the Association of Physicians of India, 63, 37-40.</mixed-citation></ref><ref id="scirp.74242-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mostafa, S.A., Khunti, K., Srinivasan, B.T., Webb, D., Gray, L.J. and Davies, M.J. (2010) The Potential Impact and Optimal Cut-Points of Using Glycated Haemoglobin, HbA1c, to Detect People with Impaired Glucose Regulation in a UK Multi-Ethnic Cohort. Diabetes Research and Clinical Practice, 90, 100-108.  
https://doi.org/10.1016/j.diabres.2010.06.008</mixed-citation></ref><ref id="scirp.74242-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Scicali, R., Giral, P., Gallo, A., Di Pino, A., Rabuazzo, A.M., Purrello, F., Cluzel, P., Redheuil, A., Bruckert, E. and Rosenbaum, D. (2016) HbA1c Increase Is Associated with Higher Coronary and Peripheral Atherosclerotic Burden in Non Diabetic Patients. Atherosclerosis, 255, 102-108.  
https://doi.org/10.1016/j.atherosclerosis.2016.11.003</mixed-citation></ref><ref id="scirp.74242-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, H.-J., Lee, Y.-H., Ra, S.K., Hyungtaek, T.R., Young, E.L., Seok, E.K., Cha, B.-S., Chul, H.L. and Lee, B.-W. (2015) Glycated Albumin and the Risk of Micro- and Macrovascular Complications in Subjects with Type 1 Diabetes. Cardiovascular Diabetology, 14, 53. https://doi.org/10.1186/s12933-015-0219-y</mixed-citation></ref><ref id="scirp.74242-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Fiorentino, T.V., Andreozzi, F., Mannino, G.C., Pedace, E., Perticone, M., Sciacqua, A., Perticone, F. and Sesti, G. (2016) One-Hour Postload Hyperglycemia Confers Higher Risk of Hepatic Steatosis to HbA1c-Defined Prediabetic Subjects. The Journal of Clinical Endocrinology &amp; Metabolism, 101, 4030-4038.  
https://doi.org/10.1210/jc.2016-1856</mixed-citation></ref><ref id="scirp.74242-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ramesh, R., Adhishwar Kumaran, N., KuzhandaiVelu, V., Reeta, R., SathishBabu, M. and Niranjan, G. (2015) Association between Hepato-Biliary Status and HbA1C in Type 2 Diabetes Mellitus with Coronary Artery Disease (CAD). Journal of Diabetes Mellitus, 5, 67-71. https://doi.org/10.4236/jdm.2015.52008</mixed-citation></ref><ref id="scirp.74242-ref25"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dyck</surname><given-names> P.J.</given-names></name>,<name name-style="western"><surname> Albers</surname><given-names> J.W.</given-names></name>,<name name-style="western"><surname> Andersen</surname><given-names> H.</given-names></name>,<name name-style="western"><surname> Arezzo</surname><given-names> J.C.</given-names></name>,<name name-style="western"><surname> Biessels</surname><given-names> G.J.</given-names></name>,<name name-style="western"><surname> Bril</surname><given-names> V.</given-names></name>,<name name-style="western"><surname> Feldman</surname><given-names> E.L.</given-names></name>,<name name-style="western"><surname> Litchy</surname><given-names> W.J.</given-names></name>,<name name-style="western"><surname> O’Brien</surname><given-names> P.C.</given-names></name>,<name name-style="western"><surname> Russell</surname><given-names> J.W. and Toronto Expert Panel on Diabetic Neuropathy </given-names></name>,<etal>et al</etal>. (<year>2011</year>)<article-title>Diabetic Polyneuropathies: Update on Research Definition, Diagnostic Criteria and Estimation of Severity</article-title><source> Diabetes/Metabolism Research and Reviews</source><volume> 27</volume>,<fpage> 620</fpage>-<lpage>628</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.74242-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Centro Nacional de Excelencia Tecnológica en Salud (2009) Diagnóstico y tratamiento de la enfermedad arterial periférica. Secretaría de Salud, México.</mixed-citation></ref><ref id="scirp.74242-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Schaper, N.C., Andros, G., Apelqvist, J., Bakker, K., Lammer, J., Lepantalo, M., Mills, J.L., Reekers, J., Shearman, C.P., Zierler, R.E. and Hinchliffe, R.J. (2012) Diagnosis and Treatment of Peripheral Arterial Disease in Diabetic Patients with a Foot Ulcer. A Progress Report of the International Working Group on the Diabetic Foot. Diabetes Metabolism Research and Reviews, 28, 218-224.  
https://doi.org/10.1002/dmrr.2255</mixed-citation></ref><ref id="scirp.74242-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Montero-Monterroso, J.L., Gascón-Jiménez, J.A., Vargas-Rubio, M.D., Quero-Salado, C., Villalba-Marín, P. and Pérula-de Torres, L.A. (2015) Prevalencia y factores asociados a la enfermedad arterial periférica en pacientes con diabetes mellitus tipo 2 en atención primaria. SEMERGEN—Medicina de Familia, 41, 183-190. https://doi.org/10.1016/j.semerg.2014.05.004</mixed-citation></ref><ref id="scirp.74242-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Pataky, Z., de LeonRodriguez, D., Allet, L., Golay, A., Assal, M., Assal, J.P. and Hauert, C.A. (2010) Biofeedback for Foot Offloading in Diabetic Patients with Peripheral Neuropathy. Diabetic Medicine, 27, 61-64.</mixed-citation></ref><ref id="scirp.74242-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Clayton, W.J. and Elasy, T.A. (2009) A Review of the Pathophysiology, Classification, and Treatment of Foot Ulcers in Diabetic Patients. Clinical Diabetes, 27, 52-58. https://doi.org/10.2337/diaclin.27.2.52</mixed-citation></ref><ref id="scirp.74242-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Huijberts M.S., Schaper, N.C. and Schalkwijk, C.G. (2008) Advanced Glycation End Products and Diabetic Foot Disease. Diabetes Metabolism Research and Reviews, 24, S19-S24. https://doi.org/10.1002/dmrr.861</mixed-citation></ref></ref-list></back></article>